Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells ; volume:9 ; number:1 ; day:14 ; month:4 ; year:2016 ; pages:1-9 ; date:12.2016
Journal of ovarian research ; 9, Heft 1 (14.4.2016), 1-9, 12.2016
- Creator
-
Abed, Mohammed Najim
- Contributor
-
Abdullah, Marwan Ibrahim
Richardson, Alan
SpringerLink (Online service)
- DOI
-
10.1186/s13048-016-0234-y
- URN
-
urn:nbn:de:1111-2016041619543
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Abed, Mohammed Najim
- Abdullah, Marwan Ibrahim
- Richardson, Alan
- SpringerLink (Online service)
Other Objects (12)
BH3-mimetics: recent developments in cancer therapy
BH3 mimetics for the treatment of prostate cancer
A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
BH3-mimetics: recent developments in cancer therapy
BH3 mimetics for the treatment of prostate cancer
A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
Evaluation of BH3 mimetics as a novel therapeutic strategy in acute myeloid leukemia
BH3-mimetics: recent developments in cancer therapy
BH3 mimetics for the treatment of prostate cancer
A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy